This could be a sign of melanoma ... The risk of shingles can be reduced with vaccines like Shingrix. The Centers for Disease Control and Prevention (CDC) recommends the Shingrix vaccine for people ...

The shingles vaccine is recommended for healthy adults age 50 or older, and also for anyone age 19 years or older who has a ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

As of now, AIM has obtained FDA approval to begin clinical trials for two major mRNA vaccine products: the mRNA shingles vaccine and the mRNA RSV vaccine. In just one month, AIM has leveraged its ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round. The fresh cash will help Curevo advance Phase 2 trials of amezosvatein ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

A small company developing a new shingles vaccine announced Monday that the venture capitalist Moncef Slaoui, who previously ran the U.S. government’s Operation Warp Speed Covid vaccine effort ...